Evoke Pharma (EVOK) |
|
2.71 -0.05 (-1.81%)
|
01-27 03:13 |
|
Open: |
2.81 |
Pre. Close: |
2.76 |
|
High:
|
2.81 |
Low:
|
2.7 |
|
Volume:
|
313,108 |
Market Cap:
|
85M |
|
|
|
|
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 6 full-time employees. The firm is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The firm has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The firm has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.813 - 2.836 |
2.836 - 2.851 |
|
Low:
|
2.653 - 2.678 |
2.678 - 2.695 |
|
Close:
|
2.678 - 2.716 |
2.716 - 2.742 |
|
Technical analysis |
as of: 2021-01-26 4:43:36 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.77 One year: 4.30 |
| Support: |
Support1: 2.50 Support2: 2.08 |
| Resistance: |
Resistance1: 3.23 Resistance2: 3.68 |
| Pivot: |
2.76  |
| Moving Average: |
MA(5): 2.81  MA(20): 2.73
MA(100): 3.72 MA(250): 2.93 |
| MACD: |
MACD(12,26): -0.04 Signal(9): -0.06 |
| Stochastic oscillator: |
%K(14,3): 20.87 %D(3): 25.78 |
| RSI: |
RSI(14): 44.80 |
| 52-week: |
High: 6.06 Low: 0.79 Change(%): 80.7 |
| Average Vol(K): |
3-Month: 35428 10-Days: 86141 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.EVOK has closed above bottom band by 38.0%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to EVOK's normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 19 Jan 2021
Evoke Pharma (NASDAQ:EVOK) Cut to Hold at Zacks Investment Research - MarketBeat
Sun, 17 Jan 2021
Evoke Pharma - Consensus Indicates Potential 226.5% Upside - DirectorsTalk Interviews
Thu, 14 Jan 2021
What is Wall Street's Target Price for Evoke Pharma Inc (EVOK) Stock? - InvestorsObserver
Thu, 14 Jan 2021
Form 424B5 Evoke Pharma Inc - StreetInsider.com
Thu, 14 Jan 2021
Evoke Pharma slips 7% after pricing equity offering - Seeking Alpha
Wed, 13 Jan 2021
Evoke Pharma Announces Pricing of Public Offering of Common Stock - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
26 |
| Shares Float (M) |
23 |
|
% Held by Insiders
|
3.92 |
|
% Held by Institutions
|
14.97 |
|
Shares Short (K)
|
469 |
|
Shares Short P. Month (K)
|
357 |
Stock Financials |
|
EPS
|
-0.493 |
|
EPS Est This Year
|
-0.820 |
|
EPS Est Next Year
|
-0.170 |
|
Book Value (p.s.)
|
-0.070 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-108.9 |
|
Return on Equity (ttm)
|
-757.3 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-6 |
|
Levered Free Cash Flow (M)
|
-2 |
Stock Valuations |
|
PE Ratio
|
-5.50 |
|
PEG Ratio
|
|
|
Price to Book value
|
-38.71 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-11.78 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
